Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025

Arcturus Therapeutics Holdings Inc.

Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.
Full year 2024 revenue $152.3M (down $14.5M YoY); net loss $80.9M ($3.00/share) vs $29.7M ($1.12).
Cash $293.9M at Dec 31, 2024; runway expected to Q1 2027; CSL reported $28M Arcturus share of KOSTAIVE gross profit.
KOSTAIVE received European Commission approval Feb 2025; US BLA filing anticipated 2025; H5N1 vaccine Phase 1 dosed.
ARCT-032 CF and ARCT-810 OTCD Phase 2 interim data on track for Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.